REDWOOD CITY, Calif.
Gynesonics, Inc., a women’s healthcare company focused on the development of minimally invasive solutions for symptomatic uterine fibroids, announced today that it has named veteran medical device executive Christopher M. Owens as President and Chief Executive Officer, effective immediately.
Owens has nearly 25 years of medical device experience and was most recently President and Chief Executive Officer at IDEV Technologies, which was acquired by Abbott Laboratories for $310 million in 2013. Prior to IDEV, from 2005-2008, Owens was Vice President of Worldwide Marketing for MicroVention, which was purchased by Terumo Corporation.
“Chris brings us significant experience in the global medical device field and a proven track record of results-based leadership,” said Karen Talmadge, Ph.D., Chair of the Gynesonics Board of Directors.
Prior to his work at MicroVention, from 2003-2005, Owens was Vice President, Global Research and Development for the Surgical Division of Bausch & Lomb.
Michael Carusi, Gynesonics Board of Director and General Partner at Advanced Technology Ventures commented: “His wide-ranging expertise in global commercialization, driving clinical excellence as well as a disciplined approach to operations, is what we need at this very important time for Gynesonics. We are very pleased to have an executive of Chris’ caliber join our team.”
Owens has a bachelor’s degree and master’s degree in plastics engineering from the University of Massachusetts, Lowell. He also has an MBA from the University of Phoenix.
“This is a tremendous opportunity that combines a highly differentiated novel technology with a significant clinical unmet need,” Owens said. “Gynesonics is developing important innovative and less invasive products for the treatment of uterine fibroids while advancing women’s healthcare. I look forward to working with this committed team and delivering on our strategic initiatives, while positioning the Company for future growth and continued success.”
About Gynesonics
Gynesonics is a women’s healthcare company focused on minimally invasive solutions for symptomatic uterine fibroids. Gynesonics has developed the VizAblate® System for the transcervical treatment of symptomatic uterine fibroids under intrauterine ultrasound guidance. VizAblate has received CE Mark approval for commercial sale in the European Union. VizAblate is not available for sale in the United States. Gynesonics is a privately-held company with headquarters in Redwood City, CA.
CONTACT
Gynesonics
Chris Owens, 650-216-3860
President and CEO
www.gynesonics.com
